EP0998571A2 - Proteases pour germes gram positif - Google Patents

Proteases pour germes gram positif

Info

Publication number
EP0998571A2
EP0998571A2 EP98934513A EP98934513A EP0998571A2 EP 0998571 A2 EP0998571 A2 EP 0998571A2 EP 98934513 A EP98934513 A EP 98934513A EP 98934513 A EP98934513 A EP 98934513A EP 0998571 A2 EP0998571 A2 EP 0998571A2
Authority
EP
European Patent Office
Prior art keywords
gram
deletion
mutation
bacillus
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98934513A
Other languages
German (de)
English (en)
Inventor
David A. Estell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International BV
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International BV, Genencor International Inc filed Critical Genencor International BV
Priority to EP98934513A priority Critical patent/EP0998571A2/fr
Publication of EP0998571A2 publication Critical patent/EP0998571A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)

Definitions

  • the present invention relates to cysteine proteases derived from gram- positive microorganisms
  • the present invention provides nucleic acid and ammo acid sequences of cysteine protease 1 , 2 and 3 identified in Bacillus
  • the present invention also provides methods for the production of cysteine protease 1 , 2 and 3 in host cells as well as the production of heterologous proteins in a host cell having a mutation or deletion of part or all of at least one of the cysteine proteases of the present invention
  • Gram-positive microorganisms such as members of the group Bacillus
  • Gram-positive bacteria have been used for large-scale industrial fermentation due, in part, to their ability to secrete their fermentation products into the culture media
  • secreted proteins are exported across a cell membrane and a cell wall and then are subsequently released into the external media usually maintaining their native conformation
  • proteases are produced in large quantities for industrial purposes.
  • a negative aspect of the presence of proteases in gram-positive organisms is their contribution to the overall degradation of secreted heterologous or foreign proteins
  • proteases found in microorganisms are based on their catalytic mechanism which results in four groups the senne proteases, metalloproteases, cysteine proteases, and aspartic proteases These categories can be distinguished by their sensitivity to various inhibitors
  • the senne proteases are inhibited by phenylmethylsulfonylfluo ⁇ de (PMSF) and diisopropylfluorophosphate (DIFP), the metalloproteases by chelating agents, the cysteine enzymes by lodoacetamide and heavy metals and the aspartic proteases by pepstatin
  • the senne proteases have alkaline pH optima
  • the metalloproteases are optimally active around neutrality
  • the cysteine and aspartic enzymes have acidic pH optima (Biotechnology Handbooks, Bacillus vol 2, edited by Harwood, 1989 Plenum Press, New York)
  • cysteine protease depends on a catalytic dyad of cysteine and histidine with the order differing among families
  • the best known family of cysteine proteases is that of papain having catalytic residues Cys-25 and H ⁇ s-159 Cysteine proteases of the papain family catalyze the hydrolysis of peptide, amide, ester, thiol ester and thiono ester bonds
  • Naturally occurring inhibitors of cysteine proteases of the papain family are those of the cystatin family (Methods in Enzymology, vol 244, Academic Press, Inc 1994) SUMMARY OF THE INVENTION
  • the present invention relates to the unexpected and surprising discovery of three heretofore unknown or unrecognized cysteine proteases found in Bacillus subtilis, designated herein as CP1 , CP2 and CP3, having the nucleic acid and ammo acid as shown in Figures 1A-1 B, Figures 5A-5B and 6A-6B, respectively
  • the present invention is based, in part, upon the presence of the characteristic cysteine protease a mo acid motif GXCWAF found in uncharacte ⁇ sed translated genomic nucleic acid sequences of Bacillus subtilis
  • the present invention is also based in part upon the structural relatedness that CP1 has with the cysteine protease papain specifically with respect to the location of the catalytic histidme/alanine and asparagine/senne residues and the structural relatedness that CP1
  • the present invention provides isolated polynucleotide and ammo acid sequences for CP1 , CP2 and CP3 Due to the degeneracy of the genetic code, the present invention encompasses any nucleic acid sequence that encodes the CP1 , CP2 and CP3 ammo acid sequence shown in the Figures
  • the present invention encompasses ammo acid variations of B subtilis CP1 , CP2 and CP3 ammo acids disclosed herein that have proteolytic activity B subtilis CP1 , CP2 and CP3, as well as proteolytically active ammo acid variations thereof, have application in cleaning compositions
  • CP1 , CP2 or CP3 obtainable from a gram-positive microorganism is produced on an industrial fermentation scale in a microbial host expression system
  • isolated and purified recombmant CP1 , CP2 or CP3 obtainable from a gram-positive microorganism is used in compositions of matter intended for cleaning purposes, such as detergents
  • the present invention provides a cleaning composition comprising at least one of CP1 , CP2 and CP3 obtainable from a gram-positive microorganism
  • the cysteine protease may be used alone in the cleaning composition or in combination with other enzymes and/or mediators or enhancers
  • the present invention also encompasses gram-positive microorganism having a mutation or deletion of part or all of the gene encoding CP1 and/or CP2 and/or CP3, which results in the mactivation of the CP1 and/or CP2 and/or CP3 proteolytic activity, either alone or in combination with deletions or mutations in other proteases, such as apr, npr, epr, mpr for example or other proteases known to those of skill in the art
  • the gram- positive organism is a member of the genus Bacillus
  • the Bacillus is Bacillus subtilis
  • the gram-positive microorganism host having one or more deletions or mutations in a cysteine protease of the present invention is further genetically engineered to produce a desired protein.
  • the desired protein is heterologous to the gram-positive host cell.
  • the desired protein is homologous to the host cell.
  • the present invention encompasses a gram- positive host cell having a deletion or interruption of the naturally occurring nucleic acid encoding the homologous protein, such as a protease, and having nucleic acid encoding the homologous protein or a variant thereof re-introduced in a recombinant form.
  • the host cell produces the homologous protein.
  • the present invention also provides methods and expression systems for reducing degradation of heterologous or homologous proteins produced in gram-positive microorganisms comprising the steps of obtaining a Bacillus host cell comprising nucleic acid encoding said heterologous protein wherein said host cell contains a mutation or deletion in at least one of the genes encoding cysteine protease 1 , cysteine protease 2 and cysteine protease 3; and growing said Bacillus host cell under conditions suitable for the expression of said heterologous protein.
  • the gram-positive microorganism may be normally sporulating or non-sporulating.
  • the present invention provides methods for detecting gram positive microorganism homologs of B. subtilis CP1 , CP2 and CP3 that comprises hybridizing part or all of the nucleic acid encoding B. subtilis CP1 , CP2 and CP3 with nucleic acid derived from gram- positive organisms, either of genomic or cDNA origin.
  • Figure 1A-1 B shows the DNA (SEQ ID NO:1) and amino acid sequence for CPI (YJDE) (SEQ ID NO:2).
  • Figure 2 shows an amino acid alignment with papain (SEQ ID NO:3) (accession number papa_carpa.p) with the cysteine protease CP1 , designated YJDE.
  • SEQ ID NO:3 accession number papa_carpa.p
  • YJDE cysteine protease CP1
  • the motif GXCWAF has been marked along with the catalytic cysteine and the conserved catalytic histidine/alanine and asparagine/serine residues.
  • Figure 3 shows amino acid alignment of CP1 (YJDE) (SEQ ID NO:2) with CP3 (PMI) (SEQ ID NO:5).
  • Figure 4 shows the amino acid alignment of CP1 (YJDE) (SEQ ID NO:2) with CP2
  • Figure 5A-5B shows the amino acid (SEQ ID NO:6) and nucleic acid sequence for CP2 (YdhS) (SEQ ID NO:7).
  • Figure 6A-6B shows the amino acid (SEQ ID NO:4) and nucleic acid sequence for CP3 (PMI) (SEQ ID NO:5).
  • Bacillus includes all members known to those of skill in the art, including but not limited to B subtilis, B hcheniformis, B lentus, B brevis, B stearothermophilus, B alkalophilus, B amyloliquefaciens, B coagulans, B ciculans, B lautus and B thunngiensis
  • the present invention relates to novel CP1 , CP2 and CP3 from gram positive organisms
  • the gram-positive organisms is a Bacillus
  • the gram-positive organism is Bacillus subtilis
  • B subtilis CP1 , CP2 or CP3 refers to the ammo acid sequences shown in Figures Figures 1A-1 B show the ammo acid and nucleic acid seqeunce for CPI (YJDE), Figures 5A- 5B show the ammo acid and nucleic acid sequence for CP2 (YDHS), and Figures 6A-6B show the ammo acid and nucleic acid sequences for CP3 (PMI)
  • the present invention encompasses ammo acid variations of the ammo acid sequences disclosed in Figures 1A- 1B and 5A-5B and 6A-6B that have proteolytic activity Such proteolytic ammo acid variants can be used in cleaning compositions
  • nucleic acid refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be double-stranded or single-stranded, whether representing the sense or antisense strand
  • am o acid refers to peptide or protein sequences or portions thereof
  • polynucleotide homolog refers to a gram-positive microorganism polynucleotide that has at least 80%, at least 90% and at least 95% identity to B subtilis CP1 , CP2 or CP3, or which is capable of hybridizing to B subtilis CP1 , CP2 or CP3 under conditions of high stringency and which encodes an ammo acid sequence having cysteine protease activity
  • isolated or “purified” as used herein refer to a nucleic acid or amino acid that is removed from at least one component with which it is naturally associated
  • heterologous protein refers to a protein or polypeptide that does not naturally occur in a gram-positive host cell
  • heterologous proteins include enzymes such as hydrolases including proteases, cellulases, amylases, carbohydrases, and lipases, isomerases such as racemases, epimerases, tautomerases, or mutases, transferases kinases and phophatases
  • the heterologous gene may encode therapeutically significant proteins or peptides, such as growth factors, cytokmes, ligands, receptors and inhibitors, as well as vaccines and antibodies
  • the gene may encode commercially important industrial proteins or peptides, such as proteases carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases
  • the gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene
  • homologous protein' refers to a protein or polypeptide native or naturally occurring in a gram-positive host cell
  • the invention includes host cells producing the homologous protein via recombmant DNA technology
  • the present invention encompasses a gram-positive host cell having a deletion or interruption of naturally occurring nucleic acid encoding the homologous protein, such as a protease and having nucleic acid encoding the homologous protein, or a variant thereof, re-introduced in a recombmant form
  • the host cell produces the homologous protein
  • the term "overexpressmg" when refe ⁇ ng to the production of a protein in a host cell means that the protein is produced in greater amounts than its production in its naturally occurring environment
  • proteolytic activity refers to a protein that is able to hydrolyze a peptide bond
  • Enzymes having proteolytic activity are described in Enzyme Nomenclature, 1992, edited Webb Academic Press, Inc.
  • the host cell is a gram-positive host cell that has a deletion or mutation in the naturally occurring cysteine protease said mutation resulting in deletion or mactivation of the production by the host cell of the proteolytic cysteine protease gene product
  • the host cell may additionally be genetically engineered to produced a desired protein or polypeptide
  • host cells may also be desired to genetically engineer host cells of any type to produce a gram-positive cysteine protease Such host cells are used in large scale fermentation to produce large quantities of the cysteine protease which may be isolated or purified and used in cleaning products, such as detergents
  • a variety of polynucleotides can encode the Bacillus subtilis CP1 , CP2 and CP3
  • the present invention encompasses all such polynucleotides
  • the present invention encompasses CP1 , CP2 and CP3 polynucleotide homologs encoding gram-positive microorganism cysteine proteases CP1 , CP2 and CP3, respectively, which have at least 80%, or at least 90% or at least 95% identity to B subtilis CP1 , CP2 and CP3 as long as the homolog encodes a protein that has proteolytic activity
  • Gram-positive polynucleotide homologs of B subtilis CP1 CP2 or CP3 may be obtained by standard procedures known in the art from, for example, cloned DNA (e g , a DNA "library”), genomic DNA libraries, by chemical synthesis once identified, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from a desired cell (See, for example, Sambrook et al , 1989, Molecular Cloning, A Laboratory Manual, 2d Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Glover, D M (ed ), 1985, DNA Cloning A Practical Approach, MRL Press, Ltd , Oxford, U K Vol I, II )
  • a preferred source is from genomic DNA Nucleic acid sequences derived from genomic DNA may contain regulatory regions in addition to coding regions Whatever the source, the isolated CP1 , CP2 or CP3 gene should be molecularly cloned into a suitable vector for propagation of
  • DNA fragments are generated, some of which will encode the desired gene
  • the DNA may be cleaved at specific sites using various restriction enzymes Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication
  • the linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography
  • identification of the specific DNA fragment containing the CP1 , CP2 or CP3 may be accomplished in a number of ways
  • a B subtilis CP1 , CP2 or CP3 gene of the present invention or its specific RNA, or a fragment thereof, such as a probe or primer may be isolated and labeled and then used in hybridization assays to detect a gram-positive CP1 , CP2 or CP3 gene (Benton, W and Davis,
  • the present invention provides a method for the detection of gram- positive CP1 , CP2 and CP3 polynucleotide homologs which comprises hybridizing part or all of a nucleic acid sequence of B subtilis CP1 CP2 and CP3 with gram-positive microorganism nucleic acid of either genomic or cDNA origin
  • gram-positive microorganism polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of B subtilis CP1 , CP2 or CP3 under conditions of intermediate to maximal stringency Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular
  • a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs
  • hybridization shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY)
  • PCR polymerase chain reaction
  • B subtilis ammo acid sequences CP1 , CP2 and CP3 were identified via a FASTA search of Bacillus subtilis genomic nucleic acid sequences B subtilis CP1 (YJDE) was identified by its structural homology to the cysteine protease papain having the sequence designated "papa_carpa p" As shown in Figure 2, YJDE has the motif GXCWAF as well as the conserved catalytic residues His/Ala and Asn/Ser CP2 (YdHS) and CP3 (PMI) were identified upon their structural homology to CP1 (YJDE) The presence of GXCWAF as well as residues His/Ala and Asn/Ser is noted in Figures 3 and 4 CP3 (PMI) was previously characterized as a possible phosphomannose isomerase, (Noramata) There has been no previous characterization of CP3 as a cysteine protease
  • the present invention provides host cells, expression methods and systems for the enhanced production and secretion of desired heterologous or homologous proteins in gram-positive microorganisms
  • a host cell is genetically engineered to have a deletion or mutation in the gene encoding a gram-positive CP1 , CP2 or CP3 such that the respective activity is deleted
  • a gram-positive microorganism is genetically engineered to produce a cysteine protease of the present invention
  • the mutation is a non- reverting mutation
  • One method for mutating nucleic acid encoding a gram-positive cysteine protease is to clone the nucleic acid or part thereof, modify the nucleic acid by site directed mutagenesis and reintroduce the mutated nucleic acid into the cell on a plasmid
  • the mutated gene may be introduced into the chromosome In the parent host cell, the result is that the naturally occurring nucleic acid and the mutated nucleic acid are located in tandem on the chromosome
  • the modified sequence is left in the chromosome having thereby effectively introduced the mutation into the chromosomal gene for progeny of the parent host cell
  • Another method for inactivating the cysteine protease proteolytic activity is through deleting the chromosomal gene copy
  • the entire gene is deleted, the deletion occurring in such as way as to make reversion impossible
  • a partial deletion is produced, provided that the nucleic acid sequence left in the chromosome is too short for homologous recombination with a plasmid encoded cysteine protease gene
  • nucleic acid encoding the catalytic ammo acid residues are deleted
  • cysteine protease gene including its 5' and 3' regions is isolated and inserted into a cloning vector
  • the coding region of the cysteine protease gene is deleted form the vector in vitro, leaving behind a sufficient amount of the 5' and 3' flanking sequences to provide for homologous recombination with the naturally occurring gene in the parent host cell
  • the vector is then transformed into the gram-positive host cell
  • the vector integrates into the chromosome via homologous recombination in the flanking regions This method leads to a gram-positive strain in which the protease gene has been deleted
  • the vector used in an integration method is preferably a plasmid
  • a selectable marker may be included to allow for ease of identification of desired recombmant microorgansims
  • the vector is preferably one which can be selectively integrated into the chromosome This can be achieved by introducing an inducible origin of replication for example, a temperature sensitive origin into the plasmid By growing the transformants at a temperature to which the origin of replication is sensitive, the replication function of the plasmid is inactivated, thereby providing a means for selection of chromosomal integrants Integrants may be selected for growth at high temperatures in the presence of the selectable marker, such as an antibiotic Integration mechanisms are described in WO 88/06623
  • Another method of inactivating the naturally occurring cysteine protease gene is to mutagenize the chromosomal gene copy by transforming a gram-positive microorganism with oligonucleotides which are mutagenic Alternatively, the chromosomal cysteine protease gene can be replaced with a mutant gene by homologous recombination
  • the present invention encompasses host cells having deletions or mutations of a cysteine protease of the present invention as well as additional protease deletions or mutations, such as deletions or mutations in apr, npr, epr, mpr and others known to those of skill in the art
  • United States Patent 5,264,366 discloses Bacillus host cells having a deletion of apr and npr
  • United States Patent 5,585,253 discloses Bacillus host cells having a deletion of epr, Margot et al , 1996
  • Microbiology 142 3437-3444 disclose host cells having a deletion in wpr
  • EP patent 0369817 discloses Bacillus host cells having a deletion of mpr
  • One assay for the detection of mutants involves growing the Bacillus host cell on medium containing a protease substrate and measuring the appearance or lack thereof, of a zone of clearing or halo around the colonies Host cells which have an inactive protease will exhibit little or no halo around the colonies
  • an expression vector comprising at least one copy of nucleic acid encoding a gram-positive microorganism CP1 , CP2 or CP3, and preferably comprising multiple copies, is transformed into the host cell under conditions suitable for expression of the cysteine protease
  • polynucleotides which encode a gram-positive microorganism CP1 , CP2 or CP3, or fragments thereof, or fusion proteins or polynucleotide homolog sequences that encode ammo acid variants of B subtilis CP1 , CP2 or CP3 may be used to generate recombmant DNA molecules that direct their expression in host cells
  • the gram-positive host cell belongs to the genus Bacillus
  • the gram positive host cell is B subtilis
  • polynucleotide sequences possessing non-naturally occurring codons Codons preferred by a particular gram-positive host cell can be selected, for example, to increase the rate of expression or to produce recombmant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence
  • Altered CP1 , CP2 or CP3 polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally equivalent CP1 , CP2 or CP3 homolog, respectively
  • a “deletion” is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively are absent
  • an "insertion” or “addition” is that change in a nucleotide or ammo acid sequence which has resulted in the addition of one or more nucleotides or ammo acid residues, respectively, as compared to the naturally occurring CP1 , CP3 or CP3
  • substitution results from the replacement of one or more nucleotides or ammo acids by different nucleotides or ammo acids, respectively
  • the encoded protein may also show deletions, insertions or substitutions of ammo acid residues which produce a silent change and result in a functionally CP1 , CP2 or CP3 variant
  • Deliberate ammo acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the variant retains the ability to modulate secretion
  • negatively charged ammo acids include aspartic acid and glutamic acid
  • positively charged ammo acids include lysme and argmine
  • ammo acids with uncharged polar head groups having similar hydrophilicity values include leucme, isoleucme, valine, glycine, alanme, asparagme, glutamine, senne threonine, phenylalanine, and tyrosme
  • CP2 or CP3 polynucleotide may be ligated to a heterologous sequence to encode a fusion protein
  • a fusion protein may also be engineered to contain a cleavage site located between the cysteine protease nucleotide sequence and the heterologous protein sequence, so that the cysteine protease may be cleaved and purified away from the heterologous moiety
  • Expression vectors used in expressing the cysteine proteases of the present invention in gram-positive microorganisms comprise at least one promoter associated with a cysteine protease selected from the group consisting of CP1 , CP2 and CP3, which promoter is functional in the host cell
  • the promoter is the wild-type promoter for the selected cysteine protease and in another embodiment of the present invention, the promoter is heterologous to the cysteine protease, but still functional in the host cell
  • nucleic acid encoding the cysteine protease is stably integrated into the microorganism genome
  • the expression vector contains a multiple cloning site cassette which preferably comprises at least one restriction endonuciease site unique to the vector, to facilitate ease of nucleic acid manipulation
  • the vector also comprises one or more selectable markers
  • selectable marker refers to a gene capable of expression in the gram-positive host which allows for ease of selection of those hosts containing the vector Examples of such selectable markers include but are not limited to antibiotics, such as, erythromycm, actinomycm, chloramphenicol and tetracyclme
  • CP1 , CP2 and CP3 A variety of host cells can be used for the production of CP1 , CP2 and CP3 including bacterial, fungal, mammalian and insects cells
  • General transformation procedures are taught in Current Protocols In Molecular Biology (vol 1 , edited by Ausubel et al , John Wiley & Sons, Inc 1987, Chapter 9) and include calcium phosphate methods, transformation using DEAE-Dextran and electroporation Plant transformation methods are taught in Rod ⁇ quez (WO 95/14099, published 26 May 1995)
  • the host cell is a gram-positive microorganism and in another preferred embodiment, the host cell is Bacillus
  • nucleic acid encoding one or more cysteine protease(s) of the present invention is introduced into a host cell via an expression vector capable of replicating within the Bacillus host cell Suitable replicating plasmids for Bacillus are described in Molecular Biological Methods for Bacillus, Ed Harwood and Cutting, John Wiley & Sons, 1990, hereby expressly incorporated by reference, see chapter 3 on plasmids Suitable replicating plasmids for B subtilis are listed on page 92
  • nucleic acid encoding a cysteine protease(s) of the present invention is stably integrated into the microorganism genome
  • Preferred host cells are gram-positive host cells
  • Bacillus Another preferred host is Bacillus subtilis
  • Several strategies have been described in the literature for the direct cloning of DNA in Bacillus Plasmid marker rescue transformation involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid (Contente et al , Plasmid 2 555-571 (1979), Haima et al , Mol Gen Genet 223 185-191 (1990), Wemrauch et al , J Bacte ⁇ ol 154(3) 1077-1087 (1983), and Weinrauch et al , J Bactenol 169(3) 1205-1211 (1987))
  • the incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chro
  • host cells which contain the coding sequence for a cysteine protease and express the protein may be identified by a variety of procedures known to those of skill in the art These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane- based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein
  • cysteine polynucleotide sequence can be detected by DNA- DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of B.subti s CP1 , CP2 or CP3
  • Means for determining the levels of secretion of a heterologous or homologous protein in a gram-positive host cell and detecting secreted proteins include, using either polyclonal or monoclonal antibodies specific for the protein Examples include enzyme- linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS) These and other assays are described, among other places, in
  • RNA polymerase such as T7, T3 or SP6 and labeled nucleotides
  • reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemilummescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like
  • Patents teaching the use of such labels include US Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241
  • recombmant immunoglobulins may be produced as shown in US Patent No 4,816,567 and incorporated herein by reference IX Purification of Proteins
  • Gram positive host cells transformed with polynucleotide sequences encoding heterologous or homologous protein may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture
  • the protein produced by a recombmant gram-positive host cell comprising a mutation or deletion of the cysteine protease activity will be secreted into the culture media
  • Other recombmant constructions may join the heterologous or homologous polynucleotide sequences to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12 441-53)
  • Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) Protein Expr Punf 3 263-281 ) protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA)
  • metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) Protein Expr Punf 3 263-281 ) protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA)
  • a cleavable linker sequence such as Factor XA or enterokmase (Invitrogen, San Diego CA) between the purification domain and the heterologous protein can be used to facilitate pur
  • CP1 CP2 and CP3 and Genetically Engineered Host Cells
  • the present invention provides genetically engineered host cells comprising preferably non-revertable mutations or deletions in the naturally occurring gene encoding CP1 , CP2 or CP3 such that the proteolytic activity is diminished or deleted altogether
  • the host cell may contain additional protease deletions, such as deletions of the mature subtilisn protease and/or mature neutral protease disclosed in United States Patent No 5,264,366
  • the host cell is further genetically engineered to produce a desired protein or polypeptide
  • the host cell is a Bacillus
  • the host cell is a Bacillus subtilis
  • a host cell is genetically engineered to produce a gram-positive CP1 , CP2 or CP3
  • the host cell is grown under large scale fermentation conditions, the CP1 , CP2 or CP3 is isolated and/or purified and used in cleaning compositions such as detergents
  • Detergent formulations are disclosed in WO 95/10615
  • a cysteine protease of the present invention can be useful in formulating various cleaning compositions
  • a number of known compounds are suitable surfactants useful in compositions comprising the cysteine protease of the invention These include nonionic, anionic, cationic, anionic or zwittenonic detergents, as disclosed in US 4,404,128 and US 4,261 ,868
  • a suitable detergent formulation is that described in Example 7 of US Patent 5,204,015
  • the art is familiar with the different formulations which can be used as cleaning compositions
  • a cysteine protease of the present invention can be used, for example, in bar or liquid soap applications, dishcare formulation
  • a cysteine protease of the present invention can be formulated into known powdered and liquid detergents having pH between 6 5 and 12 0 at levels of about 01 to about 5% (preferably 1 % to 5%) by weight
  • These detergent cleaning compositions can also include other enzymes such as known proteases amylases, cellulases, lipases or endoglycosidases, as well as builders and stabilizers
  • cysteine protease to conventional cleaning compositions does not create any special use limitation
  • any temperature and pH suitable for the detergent is also suitable for the present compositions as long as the pH is within the above range, and the temperature is below the described cysteine protease denaturing temperature
  • a cysteine protease can be used in a cleaning composition without detergents, again either alone or in combination with builders and stabilizers
  • compositions for the treatment of a textile that includes a cysteine protease of the present invention
  • the composition can be used to treat for example silk or wool as described in publications such as RD 216,034, EP 134,267, US 4,533,359, and EP 344 259
  • Proteases can be included in animal feed such as part of animal feed additives as described in, for example, US 5,612,055, US 5,314 692 and US 5,147,642
  • one aspect of the present invention is to provide for nucleic acid hybridization and PCR probes which can be used to detect polynucleotide sequences, o including genomic and cDNA sequences, encoding gram-positive CP1 , CP2 or CP3 or portions thereof
  • Genomic DNA from Bacillus cells is prepared as taught in Current Protocols In o Molecular Biology vol 1 , edited by Ausubel et al , John Wiley & Sons, Inc 1987, chapter 2
  • Sau3A recognizes the 4 base pair site GATC and generates fragments compatible with several convenient phage lambda and cosmid vectors
  • the DNA is subjected to partial o digestion to increase the chance of obtaining random fragments
  • the partially digested Bacillus genomic DNA is subjected to size fractionation on a
  • a preferred probe comprises the nucleic acid section containing the conserved motif
  • the nucleic acid probe is labeled by combining 50 pmol of the nucleic acid and 250 mCi of [gamma ⁇ P] adenosine t ⁇ phosphate (Amersham Chicago IL) and T4 polynucleotide kmase (DuPont NEN®, Boston MA) The labeled probe is purified with
  • the DNA sample which has been subjected to restriction endonuciease digestion is fractionated on a 0 7 percent agarose gel and transferred to nylon membranes (Nytran Plus,
  • blots are sequentially washed at room temperature under increasingly stringent conditions up to 0 1 x saline sodium citrate and 0 5% sodium dodecyl sulfate The blots are exposed to film for several hours the film developed and hybridization patterns are compared visually to detect polynucleotide homologs of B subtilis CP1 The homologs are subjected to confirmatory nucleic acid sequencing Methods for nucleic acid sequencing are well known in the art Conventional enzymatic methods employ DNA polymerase Klenow fragment SEQUENASE® (US Biochemical Corp, Cleveland, OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

La présente invention concerne l'identification de nouvelles cystéines protéases dans des germes Gram positif. La présente invention concerne également les séquences d'acide aminé et d'acide nucléique des cystéines protéases CP1, CP2 et CP3 identifiées dans le Bacillus subtilis. La présente invention concerne, en outre, des cellules hôtes présentant une mutation ou une délétion d'une partie ou de la totalité du gène codant CP1, CP2 et CP3. La présente invention concerne également des cellules hôtes comprenant un acide nucléique codant des protéines hétérologues désirées telles que des enzymes. La présente invention concerne, en outre, une composition de nettoyage comprenant une cystéine protéase.
EP98934513A 1997-07-15 1998-07-14 Proteases pour germes gram positif Withdrawn EP0998571A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98934513A EP0998571A2 (fr) 1997-07-15 1998-07-14 Proteases pour germes gram positif

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97305227 1997-07-15
EP97305227 1997-07-15
PCT/US1998/014529 WO1999004016A2 (fr) 1997-07-15 1998-07-14 Proteases pour germes gram positif
EP98934513A EP0998571A2 (fr) 1997-07-15 1998-07-14 Proteases pour germes gram positif

Publications (1)

Publication Number Publication Date
EP0998571A2 true EP0998571A2 (fr) 2000-05-10

Family

ID=8229413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98934513A Withdrawn EP0998571A2 (fr) 1997-07-15 1998-07-14 Proteases pour germes gram positif

Country Status (5)

Country Link
EP (1) EP0998571A2 (fr)
JP (1) JP2001510050A (fr)
AU (1) AU8401798A (fr)
CA (1) CA2296708A1 (fr)
WO (1) WO1999004016A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034597A1 (fr) * 2014-12-17 2016-06-22 The Procter and Gamble Company Composition de détergent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622916B2 (en) * 1988-05-05 1992-04-30 Applied Microbiology, Inc Protease-deficient gram-positive bacteria and their use as host organisms for the production of recombinant products
CA2003078A1 (fr) * 1988-11-18 1990-05-18 Biotechnica International, Inc. Deletion de la protease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9904016A2 *

Also Published As

Publication number Publication date
WO1999004016A2 (fr) 1999-01-28
CA2296708A1 (fr) 1999-01-28
JP2001510050A (ja) 2001-07-31
WO1999004016A3 (fr) 1999-04-15
AU8401798A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
WO1999034003A2 (fr) Proteases provenant d'organismes a gram positif
WO1999014342A1 (fr) Proteases d'organismes gram positifs
WO1999033960A2 (fr) Proteases de germes gram positifs
EP0991754A2 (fr) Proteases pour organismes gram-positifs
US7189555B2 (en) Proteases from gram-positive organisms
US6849440B2 (en) Proteases from gram-positive organisms
US6465186B1 (en) Proteases from gram positive organisms
US6599731B1 (en) Proteases from gram positive organisms
US6762039B2 (en) Bacillus subtillis with an inactivated cysteine protease-1
US7078216B2 (en) Proteases from gram positive organisms
US7033817B2 (en) Proteases from gram positive organisms
US6489108B1 (en) Proteases from gram positive organisms
WO1999004016A2 (fr) Proteases pour germes gram positif
WO1999034002A2 (fr) Proteases provenant d'organismes a gram positif
EP1042488A2 (fr) Proteases provenant d'organismes a gram positif

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENCOR INTERNATIONAL, INC.

17Q First examination report despatched

Effective date: 20030123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20061004